医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aceto Expands Life Science Manufacturing with Acquisition of Finar Limited

2021年05月17日 PM10:30
このエントリーをはてなブックマークに追加


 

PORT WASHINGTON, N.Y.

Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, announced today the acquisition of a majority stake in Finar Limited. Finar is a leading manufacturer, supplier, and distributor of pharmaceutical excipients, lab chemicals, aquaculture inputs, and food grade additives. The acquisition complements Aceto’s growth strategy, enhancing and expanding the company’s manufacturing footprint, R&D capabilities, and quality expertise.

“We are excited to bring together Finar and Aceto to give customers of both companies more solutions to support their supply chains globally,” said Gilles Cottier, CEO of Aceto. “With the Finar team’s help, we continue to strengthen our manufacturing expertise and expand our product offerings for the pharmaceutical, biopharmaceutical, and vaccine end markets.”

Finar manufactures high quality pharma ingredients including GMP/Pharma grade solvents, advanced intermediates, and GMP excipients used in both small and large molecule applications. Finar provides customers complete regulatory & documentation support including Drug Master Filing and has a strong R&D team with expertise in developing specialized excipients for complex formulations. The company is based in Ahmedabad, India.

“We’re weaving together an exciting story of growth with the acquisition of organizations that not only enhance our R&D and manufacturing capabilities but also align with our customer centric philosophy,” added Gilles Cottier. “Finar’s established reputation as a partner and supplier to the global pharma industry, and commitment to producing high quality products, mirrors Aceto’s guiding business principles and is complementary to our other recent acquisitions of Syntor, A&C and IsleChem.”

“We live by our motto of consistently providing customers high-quality products and exceeding their expectations,” said Amit Maheshwari, CEO of Finar Limited. “Both Finar and Aceto create long-term relationships with customers by providing best-in-class customer service and treating each customer with integrity and respect. These attributes are an important part of our company culture and we appreciate that Aceto shares this business philosophy. We look forward to providing our combined customers with access to our manufacturing expertise and diversified product portfolio.”

Aceto will continue to support Finar’s manufacturing facilities and offices in India.

Lincoln International acted as the exclusive financial advisor to Finar and its shareholders.

For more information, please visit Aceto.com.

About Aceto

Founded in 1947, Aceto is a leading global provider of differentiated specialty materials in life sciences and advanced technology end markets. With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries. Aceto’s global operations, including a significant staff on the ground in China, India, Europe and North America, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities. www.aceto.com

About Finar:

Finar has evolved as a fast-growing life sciences company that has steadily built its manufacturing base and product portfolio. Beginning as a manufacturer of Laboratory Chemicals, the company has since increased offerings to over 1000 products and diversified product categories to also include Pharmaceutical Excipients and Solvents, Food Grade Additives, Aquaculture Specialties and Safety & Hygiene Products, all of which have withstood rigorous international quality control procedures. Serving more than 10,000 customers across industries in domestic and international markets, Finar’s strong distribution network and sales force enables them to reach customers across India and overseas in over 50 countries. For more information visit www.finarchemicals.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005040/en/

CONTACT

Kate Blom-Lowery

CG Life

kblomlowery@cglife.com

(619) 743-6294

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 武田实现强劲的2021财年业绩;预计增长势头将在2022财年持续
  • PurrSong Targets US Market with Its IoT-based Cat Healthcare Solutions
  • iMediSync Leads Global Remote Healthcare Market With Its AI-Based Brain Scanning Device iSyncWave
  • LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York
  • CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress